Indications
Therapeutic Asset Ratings
3,186 results matching 1 filter
91,565
assets
·
7,904
sponsors
·
3,128
indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Anti-Cd19 Car Nk Cells
Diffuse Large B-Cell Lymphoma
Changhai Hospital
Early P1
C
(36)
Anti-Cd19 Car T-Cells
Lymphoma
Affiliated Hospital of Nantong University
Early P1
C
(36)
Anti Cd30 Car-T Cell
Anaplastic Large Cell Lymphoma
Zhejiang University
Early P1
C
(36)
Autologous Car123 T Lymphocytes
Acute Myeloid Leukemia
Institute of Hematology and Blood Transfusion, Czech Republic
Early P1
C
(36)
Autologous, Engineered T Cells Targeting Tp53 R248Q
Malignant Pancreatic Neoplasm
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Early P1
C
(36)
Bcma Targeted Car T-Cells
Plasma Cell Myeloma
The First Affiliated Hospital of Nanchang University
Early P1
C
(36)
car19-bcma dual-target car-t
Plasma Cell Myeloma
Institute of Hematology & Blood Diseases Hospital, China
Early P1
C
(36)
cdh17 car-t
Biliary Tract Cancer
Zhejiang University
Early P1
C
(36)
Chimeric Antigen Receptor Nk Cell Targeting Bcma
Plasma Cell Myeloma
Shenzhen Pregene Biopharma Co., Ltd.
Early P1
C
(36)
Cytokine Induced Memory-Like Natural Killer Cells
Urothelial Carcinoma
Dana-Farber Cancer Institute
Early P1
C
(36)
Fast Laco-Stim Cdh17 Car-T
Biliary Tract Cancer
Zhejiang University
Early P1
C
(36)
Hema-Neotil01
B-Cell Acute Lymphoblastic Leukemia
The First Affiliated Hospital of Soochow University
Early P1
C
(36)
Human Bcma Targeted Car-Nk Cells
Plasma Cell Myeloma
Hrain Biotechnology Co., Ltd.
Early P1
C
(36)
Human Derived Anti-Bcma Car-T
Plasma Cell Myeloma
Hrain Biotechnology Co., Ltd.
Early P1
C
(36)
il-15 enhanced engineered nk cells
Metastatic Malignant Neoplasm
Genovn Therapeutics (Suzhou) Co., Ltd.
Early P1
C
(36)
kt032
Colon Carcinoma
Weijia Fang, MD
Early P1
C
(36)
Metabolically Armed Cd19 Car-T Cells
Diffuse Large B-Cell Lymphoma
He Huang
Early P1
C
(36)
nk521 cell
Hepatocellular Carcinoma
Base Therapeutics (Shanghai) Co., Ltd.
Early P1
C
(36)
rd14-01 cell
Diffuse Large B-Cell Lymphoma
He Huang
Early P1
C
(36)
Anti-Cd19 Autologous Car-T Cell Infusion
B-Cell Non-Hodgkin Lymphoma
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
P1/2
C
(36)
Anti-Cd19 Ucar-Nk Cells
B-Cell Non-Hodgkin Lymphoma
Kunming Hope of Health Hospital
P1/2
C
(36)
Autologous Hucd19 Car T Cells
B-Cell Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
P1/2
C
(36)
Clls52
B-Cell Acute Lymphoblastic Leukemia
Cellectis S.A.
P1/2
C
(36)
Ucart22
B-Cell Acute Lymphoblastic Leukemia
Cellectis S.A.
P1/2
C
(36)
Allogeneic Natural Killer Cells
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Paolo Caimi, MD
P1
C
(35)
Showing 2401 to 2425 of 3,186 assets
Previous
Page 97 of 128
Next
